deCODE Announces Appointment of Peter Goodfellow to Board of Directors
deCODE genetics announced that it has named Dr. Peter Goodfellow to its Board of Directors, effective immediately.
Dr. Goodfellow was until recently Senior Vice President for Discovery Research at GlaxoSmithKline, a position he held for the past six years. Prior to this post, he held senior positions at SmithKline Beecham, the Balfour chair in genetics at Cambridge University and research positions at the Imperial Cancer Research Fund. Dr. Goodfellow received his doctorate from Oxford University and held a postdoctoral fellowship at Stanford University.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

New Technology Makes Tumor Eliminate Itself - Trojan horse to deliver genes for cancer therapeutics directly into tumor cells
New receptor found on scavenger cells - How adenoviruses invade the immune system of mice

XPhyto signs transformative acquisition agreement with 3a-diagnostics - Enter hi-tech biosensor market and expand its diagnostic product portfolio

Stat Profile Prime CCS Comp | Cell culture systems | Nova Biomedical

A Guide to Common Fruit Acids
